RESEARCH TRIANGLE PARK, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 29, 2024 (the “Circular”) for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders held in New York, New York on June 25, 2024.
Detailed results of the vote for the election of directors are set out below:
| Name of Nominee | Votes For | % Votes For | Votes Withheld | % Votes Withheld |
| Dr. Khalid Islam | 10,100,238 | 96.45% | 371,270 | 3.54% |
| Mr. Chris A. Rallis | 9,688,517 | 92.52% | 782,991 | 7.47% |
| Mr. Marco Brughera | 9,801,305 | 93.59% | 670,203 | 6.40% |
| Dr. Jodi Cook | 8,991,182 | 85.86% | 1,480,326 | 14.14% |
| Mr. Rostislav Raykov | 9,859,679 | 94.15% | 611,829 | 5.84% |
Shareholders voted 97.96% in favour of appointing Haskell & White LLP as auditors and authorizing the directors to fix the auditor remuneration, 93.87% in favour of the compensation paid to the Company’s named executive officers.
For further information, please contact:
Rosty Raykov
Chief Executive Officer
Fennec Pharmaceuticals Inc.
T: (919) 636-5144
| Last Trade: | US$3.99 |
| Daily Change: | -0.41 -9.32 |
| Daily Volume: | 126,664 |
| Market Cap: | US$109.170M |
November 07, 2024 October 28, 2024 August 13, 2024 August 05, 2024 May 14, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
